2020 started with an important discussion about the terminology to be used regarding Non Alcoholic Fatty Liver Disease (NAFLD). In this exclusive interview for the PanNASH web site, Prof Sven Francque discusses the rationale of this change and the possible impact in clinical practice
Peroxisome prolifrator activated receptors

Peroxisome prolifrator activated receptors

, by

PPARs are highly relevant to NAFLD28. When it is approached from the standpoint of a systemic disease involving metabolic changes in Adipose tissue, skeletal muscle, liver and endothelium.

The role of insulin resistance and insulin-sensitizers in NASH management: tips for the practicing clinician.

The role of insulin resistance and insulin-sensitizers in NASH management: tips for the practicing clinician

, by

Prof Kenneth Cusi, USA, discusses the role of insulin sensitizers in NASH, and particularly how lifestyle interventions including weight loss can, in this context, be beneficial together with a pharmacological approach. This video was filmed in Boston during the Liver meeting 2019.

Prof Jean-François Dufour, Switzerland, addresses the important problem of comorbidities in NASH management including diabetes, cardiovascular disease, cancer. This video was filmed in Boston during the Liver meeting 2019.

The role of comorbidities in NASH management: a holistic approach

, by

Prof Jean-François Dufour, Switzerland, addresses the important problem of comorbidities in NASH management including diabetes, cardiovascular disease, cancer. This video was filmed in Boston during the Liver meeting 2019.

Prof Pierre-Emmanuel Rautou, France sheds light on the role of liver sinusoidal endothelial cells in NASH development. This video was flmed in Boston during the Liver meeting 2019.

The role of liver sinusoidal endothelial cells

, by

Prof Michael Roden, Germany discusses the reasons why patients with NASH have an increased cardiovascular risk and the potential for PPAR agonists to improve outcomes. This video was filmed in Boston during the Liver meeting 2019.

Prof Gracia-Sancho, Spain, discusses his oral presentation at the Liver meeting 2019 in Boston and the reasons why PPAR agonists could be a very valuable therapeutic option for the treatment of advanced chronic liver disease.

Pre-clinical study with Lanifibranor – Prof Gracia-Sancho

, by

Prof Michael Roden, Germany discusses the reasons why patients with NASH have an increased cardiovascular risk and the potential for PPAR agonists to improve outcomes. This video was filmed in Boston during the Liver meeting 2019.

Prof Michael Roden, Germany discusses the reasons why patients with NASH have an increased cardiovascular risk and the potential for PPAR agonists to improve outcomes. This video was filmed in Boston during the Liver meeting 2019.

The role of PPARs in NASH fibrogenesis

, by

Prof Michael Roden, Germany discusses the reasons why patients with NASH have an increased cardiovascular risk and the potential for PPAR agonists to improve outcomes. This video was filmed in Boston during the Liver meeting 2019.